FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1854786812> ?p ?o ?g. }

• W1854786812 endingPage "633" @default.
• W1854786812 startingPage "633" @default.
• W1854786812 abstract "Background: Pheochromocytomas (PHEO) and paragangliomas (PGL) are derived from paraganglia of the sympathetic and parasympathetic nervous system. Most of the sympathetic PHEO/PGL secrete either catecholamine or their metabolites, metanephrines, whereas parasympathetic PHEO/PGL are nonsecretory. We assessed the utility of plasma free 3-methoxytyramine (3MT), normetanephrine (NM), and metanephrine (MN) for the diagnosis of PHEO/PGL. Materials and Methods: Sixty-five patients referred to endocrine/ENT clinics were enrolled. Twelve patients with von Hippel-Lindau (VHL), neurofibromatosis type 1 (NF1) and multiple endocrine neoplasia type 2 (MEN2) syndromes were excluded. Remaining 53 patients (39 patients with adrenal, abdominal, cervical and thoracic PHEO/PGL and 14 patients with head and neck PGL (HNPGL) were taken for this study. Sixty-five age- and sex-matched subjects were taken as controls. Plasma levels 3MT, NM, and MN were measured using high-performance liquid chromatography. Receivers operating characteristics was plotted and cut-off levels were established. Results: When compared with controls, there was a 36-, 8.7- and 9.5-fold increase in levels of NM, 3MT and MN in the patients with PHEO/PGL and 7.2- and 2.7-fold increase in 3MT and NM, in the patients with HNPGL, respectively. In malignant PHEO/PGL, there was a 99-, 16- and 20-fold increase and in benign PHEO/PGL, there was 19-, 6.8- and 6.4-fold increase in levels of NM, 3MT, and MN, respectively. NM in combination with MN was high in 97% of the patients with PHEO/PGL. All three metabolites in combination were high in 83% of patients with HNPGL. In malignant PHEO/PGL, 50% subjects had increased levels of both NM and 3MT. Conclusions: Measurement of plasma-free NM along with 3MT and MN provides a better tool for the diagnosis of PHEO/PGL as well as HNPGL. Further, NM in combination with 3MT can be used for the diagnosis of malignant PHEO/PGL." @default.
• W1854786812 created "2016-06-24" @default.
• W1854786812 creator A5018621533 @default.
• W1854786812 creator A5029733873 @default.
• W1854786812 creator A5060983000 @default.
• W1854786812 creator A5065357576 @default.
• W1854786812 creator A5068701943 @default.
• W1854786812 creator A5088906706 @default.
• W1854786812 creator A5090506078 @default.
• W1854786812 date "2015-01-01" @default.
• W1854786812 modified "2023-10-05" @default.
• W1854786812 title "Plasma free metanephrine, normetanephrine, and 3-methoxytyramine for the diagnosis of pheochromocytoma/paraganglioma" @default.
• W1854786812 cites W1829035741 @default.
• W1854786812 cites W1971120269 @default.
• W1854786812 cites W1979170245 @default.
• W1854786812 cites W1979422997 @default.
• W1854786812 cites W1982630125 @default.
• W1854786812 cites W1986576905 @default.
• W1854786812 cites W2007599332 @default.
• W1854786812 cites W2035287899 @default.
• W1854786812 cites W2053473747 @default.
• W1854786812 cites W2057275256 @default.
• W1854786812 cites W2067772434 @default.
• W1854786812 cites W2073136964 @default.
• W1854786812 cites W2076487247 @default.
• W1854786812 cites W2101065691 @default.
• W1854786812 cites W2103071432 @default.
• W1854786812 cites W2122001473 @default.
• W1854786812 cites W2122845403 @default.
• W1854786812 cites W2125250790 @default.
• W1854786812 cites W2133884882 @default.
• W1854786812 cites W2134010618 @default.
• W1854786812 cites W2163960412 @default.
• W1854786812 cites W4210969235 @default.
• W1854786812 doi "https://doi.org/10.4103/2230-8210.163183" @default.
• W1854786812 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4566344" @default.
• W1854786812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26425473" @default.
• W1854786812 hasPublicationYear "2015" @default.
• W1854786812 type Work @default.
• W1854786812 sameAs 1854786812 @default.
• W1854786812 citedByCount "6" @default.
• W1854786812 countsByYear W18547868122017 @default.
• W1854786812 countsByYear W18547868122020 @default.
• W1854786812 countsByYear W18547868122021 @default.
• W1854786812 countsByYear W18547868122023 @default.
• W1854786812 crossrefType "journal-article" @default.
• W1854786812 hasAuthorship W1854786812A5018621533 @default.
• W1854786812 hasAuthorship W1854786812A5029733873 @default.
• W1854786812 hasAuthorship W1854786812A5060983000 @default.
• W1854786812 hasAuthorship W1854786812A5065357576 @default.
• W1854786812 hasAuthorship W1854786812A5068701943 @default.
• W1854786812 hasAuthorship W1854786812A5088906706 @default.
• W1854786812 hasAuthorship W1854786812A5090506078 @default.
• W1854786812 hasBestOaLocation W18547868121 @default.
• W1854786812 hasConcept C104317684 @default.
• W1854786812 hasConcept C126322002 @default.
• W1854786812 hasConcept C126894567 @default.
• W1854786812 hasConcept C134018914 @default.
• W1854786812 hasConcept C13514818 @default.
• W1854786812 hasConcept C142724271 @default.
• W1854786812 hasConcept C185592680 @default.
• W1854786812 hasConcept C2776512331 @default.
• W1854786812 hasConcept C2776734335 @default.
• W1854786812 hasConcept C2776783082 @default.
• W1854786812 hasConcept C2778984943 @default.
• W1854786812 hasConcept C2779161898 @default.
• W1854786812 hasConcept C2779505177 @default.
• W1854786812 hasConcept C2779512018 @default.
• W1854786812 hasConcept C2780103800 @default.
• W1854786812 hasConcept C501734568 @default.
• W1854786812 hasConcept C55493867 @default.
• W1854786812 hasConcept C71924100 @default.
• W1854786812 hasConcept C90924648 @default.
• W1854786812 hasConceptScore W1854786812C104317684 @default.
• W1854786812 hasConceptScore W1854786812C126322002 @default.
• W1854786812 hasConceptScore W1854786812C126894567 @default.
• W1854786812 hasConceptScore W1854786812C134018914 @default.
• W1854786812 hasConceptScore W1854786812C13514818 @default.
• W1854786812 hasConceptScore W1854786812C142724271 @default.
• W1854786812 hasConceptScore W1854786812C185592680 @default.
• W1854786812 hasConceptScore W1854786812C2776512331 @default.
• W1854786812 hasConceptScore W1854786812C2776734335 @default.
• W1854786812 hasConceptScore W1854786812C2776783082 @default.
• W1854786812 hasConceptScore W1854786812C2778984943 @default.
• W1854786812 hasConceptScore W1854786812C2779161898 @default.
• W1854786812 hasConceptScore W1854786812C2779505177 @default.
• W1854786812 hasConceptScore W1854786812C2779512018 @default.
• W1854786812 hasConceptScore W1854786812C2780103800 @default.
• W1854786812 hasConceptScore W1854786812C501734568 @default.
• W1854786812 hasConceptScore W1854786812C55493867 @default.
• W1854786812 hasConceptScore W1854786812C71924100 @default.
• W1854786812 hasConceptScore W1854786812C90924648 @default.
• W1854786812 hasIssue "5" @default.
• W1854786812 hasLocation W18547868121 @default.
• W1854786812 hasLocation W18547868122 @default.
• W1854786812 hasLocation W18547868123 @default.
• W1854786812 hasLocation W18547868124 @default.
• W1854786812 hasOpenAccess W1854786812 @default.

• next